Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
AGEN
HOLDAgenus Inc. · Healthcare · United States · $249M · Avg Vol: $46M/d
COMPANY DESCRIPTION
Agenus Inc. is a clinical-stage immuno-oncology company focused on discovering and developing novel antibodies and cell therapies to treat cancer, including checkpoint modulators and cancer vaccines. The company's competitive moat is built on its proprietary technology platforms and extensive intellectual property, supported by strategic partnerships with major pharmaceutical firms, positioning it in the cutting-edge field of cancer immunotherapy.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 98.0M | 156.3M | 103.5M | 114.2M | 5.2% | 123.9M | 184.7M | 131.5M | 7.3% |
| EPS | -5.74 | -6.51 | -10.59 | 0.00 | — | 2.04 | — | — | — |
| Shares | 41.6M | 41.6M | 23.6M | 35.3M | -15.2% | 41.6M | — | — | — |
| Debt | 78.4M | 88.5M | 94.9M | 55.9M | -10.7% | 41.1M | — | — | — |
| Equity | -61.3M | -160.3M | -326.4M | -271.1M | — | — | — | — | — |
| Op CF | -175.4M | -224.2M | -158.3M | -77.2M | — | -87.5M | — | — | — |
| Inv CF | -33.6M | 3.4M | 27.0K | 1.2M | — | — | — | — | — |
| Fin CF | 95.8M | 119.9M | 122.8M | 36.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AGEN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| AGEN | Agenus Inc.(you) | $249M | 61 | HOLD |
| ABEO | Abeona Therapeutics Inc. | $345M | 59 | HOLD |
| ORMP | Oramed Pharmaceuticals Inc. | $165M | 58 | HOLD |
| NAGE | Niagen Bioscience, Inc. | $256M | 73 | BUY |
| FENC | Fennec Pharmaceuticals Inc. | $347M | 54 | HOLD |
| FBIO | Fortress Biotech, Inc. | $111M | 59 | HOLD |
| 0JDK.L | Iovance Biotherapeutics, Inc. | $638M | 64 | HOLD |
| CSBR | Champions Oncology, Inc. | $85M | 58 | HOLD |
| RLMD | Relmada Therapeutics, Inc. | $544M | 51 | HOLD |
| DTIL | Precision BioSciences, Inc. | $188M | 40 | HOLD |
Peer medians: ROE -25.6% · P/E 27.7x · Gross margin 50.5%